Trevi Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for chronic conditions with high unmet medical needs
The company's primary focus is on utilizing its proprietary formulation technology to create treatments for neurological and chronic pain disorders, including pruritus associated with specific dermatological conditions. Through advanced research and clinical trials, Trevi aims to bring new, effective solutions to patients suffering from debilitating symptoms, thereby improving their quality of life.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQIDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSETAK) is likely to report earnings for its fourth quarter. • Exela Technologies NASDAQ:XELANASDAQXELA)
